Ragnhild J Måseide1,2,3, Erik Berntorp4, Jan Astermark4,5, Anna Olsson6, Maria Bruzelius7,8, Tony Frisk9, Vuokko Nummi10, Riitta Lassila10, Geir E Tjønnfjord1,3, Pål A Holme1,2,3. 1. Department of Haematology, Oslo University Hospital, Oslo, Norway. 2. Research Institute of Internal Medicine, Oslo University Hospital, Oslo, Norway. 3. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 4. Department of Translational Medicine, Lund University, Malmö, Sweden. 5. Department of Haematology, Skåne University Hospital, Malmö, Sweden. 6. Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden. 7. Molecular Medicine and Surgery, Karolinska Institute, Stockholm, Sweden. 8. Department of Haematology, Karolinska University Hospital, Stockholm, Sweden. 9. Pediatric Coagulation, Karolinska University Hospital, Stockholm, Sweden. 10. Coagulation Disorders Unit, Haematology, Comprehensive Cancer Centre, Helsinki University Hospital and Research Program in Systems Oncology, Faculty of Medicine, Helsinki University, Helsinki, Finland.
Abstract
INTRODUCTION: The prevalence of arthropathy in moderate haemophilia A (MHA) and B (MHB) is not well known. AIM: We evaluated joint health in Nordic patients in relation to their treatment modality. METHODS: A cross-sectional, multicentre study covering MHA and MHB in Sweden, Finland and Norway. Arthropathy was evaluated by ultrasound (HEAD-US) and Haemophilia Joint Health Score (HJHS). RESULTS: We report on 145 patients: median age 28 years (IQR 13-52) and 61% MHA. Baseline factor VIII/factor IX activity (FVIII/FIX:C) was 2 IU/dL (median) (IQR 2-4): lower for MHB (2 IU/dL, IQR 1-2) than MHA (3 IU/dL, IQR 2-4) (P < .01). Eighty-five per cent of MHA and 73% MHB had a history of haemarthrosis (P = .07). Age at first joint bleed was lower for MHA (5 years [median], IQR 3-7) than MHB (7 years, IQR 5-12) (P = .01). Thirty-eight per cent received prophylaxis, started at median 10 years of age (IQR 4-24). Median joint bleeds and serious other bleeds during the last 12 months were both zero (IQR 0-1). Total HEAD-US captured 0/48 points (median) (IQR 0-2) and HJHS 4/120 points (IQR 1-10) with strong correlation between them (r = .72). FVIII/FIX: C ≤ 3 IU/dL was associated with higher HJHS (P = .04). Fifteen per cent had undergone orthopaedic surgery. CONCLUSION: The current joint health in Nordic moderate haemophilia patients was rather good, but a subgroup had severe arthropathy. FVIII/FIX: C ≤ 3 IU/dL and MHA were associated with a more severe bleeding phenotype. We suggest primary prophylaxis to all patients with FVIII/FIX:C ≤ 3 IU/dL.
INTRODUCTION: The prevalence of arthropathy in moderate haemophilia A (MHA) and B (MHB) is not well known. AIM: We evaluated joint health in Nordic patients in relation to their treatment modality. METHODS: A cross-sectional, multicentre study covering MHA and MHB in Sweden, Finland and Norway. Arthropathy was evaluated by ultrasound (HEAD-US) and Haemophilia Joint Health Score (HJHS). RESULTS: We report on 145 patients: median age 28 years (IQR 13-52) and 61% MHA. Baseline factor VIII/factor IX activity (FVIII/FIX:C) was 2 IU/dL (median) (IQR 2-4): lower for MHB (2 IU/dL, IQR 1-2) than MHA (3 IU/dL, IQR 2-4) (P < .01). Eighty-five per cent of MHA and 73% MHB had a history of haemarthrosis (P = .07). Age at first joint bleed was lower for MHA (5 years [median], IQR 3-7) than MHB (7 years, IQR 5-12) (P = .01). Thirty-eight per cent received prophylaxis, started at median 10 years of age (IQR 4-24). Median joint bleeds and serious other bleeds during the last 12 months were both zero (IQR 0-1). Total HEAD-US captured 0/48 points (median) (IQR 0-2) and HJHS 4/120 points (IQR 1-10) with strong correlation between them (r = .72). FVIII/FIX: C ≤ 3 IU/dL was associated with higher HJHS (P = .04). Fifteen per cent had undergone orthopaedic surgery. CONCLUSION: The current joint health in Nordic moderate haemophiliapatients was rather good, but a subgroup had severe arthropathy. FVIII/FIX: C ≤ 3 IU/dL and MHA were associated with a more severe bleeding phenotype. We suggest primary prophylaxis to all patients with FVIII/FIX:C ≤ 3 IU/dL.
Authors: Alban Fouasson-Chailloux; Fabien Leboeuf; Yves Maugars; Marc Trossaert; Pierre Menu; François Rannou; Claire Vinatier; Jérome Guicheux; Raphael Gross; Marc Dauty Journal: Int J Environ Res Public Health Date: 2022-06-20 Impact factor: 4.614
Authors: Erik Berntorp; Kathelijn Fischer; Daniel P Hart; Maria Elisa Mancuso; David Stephensen; Amy D Shapiro; Victor Blanchette Journal: Nat Rev Dis Primers Date: 2021-06-24 Impact factor: 52.329
Authors: Fabienne R Kloosterman; Anne-Fleur Zwagemaker; Catherine N Bagot; Erik A M Beckers; Giancarlo Castaman; Marjon H Cnossen; Peter W Collins; Charles Hay; Michel Hof; Britta Laros-van Gorkom; Frank W G Leebeek; Christoph Male; Karina Meijer; Ingrid Pabinger; Susan Shapiro; Michiel Coppens; Karin Fijnvandraat; Samantha C Gouw Journal: Blood Adv Date: 2022-07-26
Authors: Erik Berntorp; Petra LeBeau; Margaret V Ragni; Munira Borhany; Yasmina L Abajas; Michael D Tarantino; Katharina Holstein; Stacy E Croteau; Raina Liesner; Cristina Tarango; Manuela Carvalho; Catherine McGuinn; Eva Funding; Christine L Kempton; Christoph Bidlingmaier; Alice Cohen; Johannes Oldenburg; Susan Kearney; Christine Knoll; Philip Kuriakose; Suchitra Acharya; Ulrike M Reiss; Roshni Kulkarni; Michelle Witkop; Stefan Lethagen; Rebecca Krouse; Amy D Shapiro; Jan Astermark Journal: Haemophilia Date: 2022-03-08 Impact factor: 4.263
Authors: Anne-Fleur Zwagemaker; Fabienne R Kloosterman; Robert Hemke; Samantha C Gouw; Michiel Coppens; Lorenzo G R Romano; Marieke J H A Kruip; Marjon H Cnossen; Frank W G Leebeek; Barbara A Hutten; Mario Maas; Karin Fijnvandraat Journal: J Thromb Haemost Date: 2022-03-07 Impact factor: 16.036